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Abstract
Background: A randomized clinical trial has found that the addition of erlotinib to gemcitabine (GEM-E) for
pancreatic cancer led to a modest increase in survival. The aim of this national population-based retrospective
study was to compare the effectiveness of GEM-E to GEM alone for pancreatic cancer patients in real clinical
practice.
Methods: Patients with pancreatic cancer (ICD-10: C25) with prescription claims of gemcitabine or erlotinib
between Jan 1, 2007 and Dec 31, 2012 were retrospectively identified from the Korean Health Insurance claims
database. To be included in the study population, patients were required to have had a histological or cytological
diagnosis within one year before chemotherapy. Patients treated with prior radiotherapy, surgery, or chemotherapy
were excluded to reduce heterogeneity. Overall survival from the initiation of therapy and the medical costs of
GEM-E and GEM were compared.
Results: A total of 4,267 patients were included in the analysis. Overall survival was not significantly longer in
patients treated with GEM-E (median 6.77 months for GEM-E vs. 6.68 months for GEM, p = 0.0977). There was also
no significant difference in the respective one-year survival rates (27.0 % vs. 27.3 %; p = 0.5988). Multivariate analysis
using age, gender, and comorbidities as covariates did not reveal any significant differences in survival. Based on
this relative effectiveness, the incremental cost per life year gained over GEM was estimated at USD 70,843.64 for
GEM-E.
Conclusions: GEM-E for pancreatic cancer is not more effective than GEM in a real-world setting, and it does not
provide reasonable cost-effectiveness over GEM.
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Background
Pancreatic cancer is a major problem, causing 266,000
estimated deaths per year worldwide, with an estimated
mortality-incidence ratio of 0.95 [1]. In South Korea, it
currently ranks eighth in incidence and fifth in cancer-
related mortality. The 5-year overall survival (OS) is less
than 10 % [2]. At the time of diagnosis, approximately
half the patients with pancreatic cancer have metastases,
and their median survival does not exceed 6 months [3].
Despite efforts to improve therapeutic strategies, the 5-
year OS has not increased significantly over the past
decade [4, 5].
Gemcitabine (GEM) has provided survival superior to
bolus 5-FU, and for more than a decade has been con-
sidered to be the standard treatment for metastatic
pancreatic cancer [6, 7]. GEM-based combination regi-
mens were subsequently evaluated for superiority over
GEM alone in clinical trials [8, 9]. However, with the ex-
ception of erlotinib, the addition of targeted agents to
GEM has failed to produce any added benefit [10, 11].
The combination of gemcitabine and erlotinib (GEM-E)
showed a modest increase in survival (median survival
6.24 months vs. 5.91 months, 1-year survival increased
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to 23 % from 17 %, compared with GEM alone) [12, 13].
Although the improvement in survival provided by the
combination was statistically significant, it is questionable
whether the two-week improvement in survival is clinic-
ally meaningful. Moreover, an actual improvement in real
clinical practice is also questionable, considering the dif-
ference between controlled trials and the real world.
Since the randomized phase III trial that showed im-
provement for GEM-E [12], it was approved by South
Korean Food and Drug Administration as the first-line
treatment for patients with advanced pancreatic cancer.
GEM-E has been reimbursed by the Korean Ministry of
Health and Welfare and the National Health Insurance
Service (NHIS) since 2006. This reimbursement policy
reflects the urgent need for more effective treatment for
advanced pancreatic cancer. However, because of the
concerns about the real-world efficacy of GEM-E, it has
been proposed that there is a need for reassessment
using a national database.
Use of the NHIS database to quantify treatment
utilization and effectiveness of treatment in routine
practice has several advantages. First, South Korea pro-
vides universal health insurance coverage. NHIS covers
approximately 97 % of the entire 50.6 million South
Korean population and is fairly representative of the
Korean population. Second, NHIS includes data on the
diagnosis, which is recorded according to the Inter-
national Classification of Diseases, 10th revision (ICD-
10); procedures; prescriptions (drug name, formula,
dose, duration of prescription, costs); and demographics.
With the NHIS database, it is possible to monitor from
a payer perspective the impact of adopting new drugs on
resource utilization and the effectiveness of new treat-
ments used in routine clinical practice. These databases
have been used in previous studies [14–18].
This retrospective study aimed to evaluate the effect-
iveness and cost effectiveness of GEM-E compared to
GEM for pancreatic cancer patients, using data from the
South Korean NHIS claims database.
Methods
Selection of patients with pancreatic cancer
This was a population-based, retrospective analysis using
the NHIS database to identify patients with pancreatic
cancer who began chemotherapy with GEM-E or GEM
between January 1, 2007 and December 31, 2012.
The study population included patients who received
GEM therapy by injection for pancreatic cancer (ICD-
10: C25). Within study population, GEM-E patients were
identified if erlotinib was prescribed with gemcitabine
injection at index date. Patients were required to have a
history of intervention for histological or cytological
diagnosis within one year before the index date, because
the final results of these evaluations were not available
from the database. To avoid possible heterogeneity of
the patients, patients initially presenting with metastatic
pancreatic cancer treated with first-line chemotherapy
with GEM or GEM-E were included in this study, ex-
cluding those who received prior radiotherapy or surgi-
cal treatment before GEM or GEM-E.
Patients with a history of receiving GEM before 2007
were excluded. We also excluded patients who had a diag-
nosis of hepatobiliary cancer (C24), bronchial and lung
cancer (C34), breast cancer (C50), ovarian cancer (C56),
and bladder cancer (C67), each within 5 years before and
after the index date; those who were diagnosed with pan-
creatic neuroendocrine cancer (C25.4) after cohort entry;
those who received GEM as a therapy for other cancers;
and those who were younger than 18 years.
The Charlson Comorbidity Index (CCI) score was
used to assess the overall burden of comorbidity [19].
Patients were followed for three years or until date of
death or end of the study period (December 31, 2013),
whichever came first.
Because the claims data that were used were fully dei-
dentified, approval from the Institutional Review Board
was not required for this study.
Clinical and economic outcomes
The clinical outcome of the study was overall survival,
which was calculated from the date of GEM or GEM-E
to the date of death from any cause. Medical cost per
patient for GEM-E and GEM was measured using claims
data during the entire follow-up period. Total medical
costs were calculated as the sum of medication costs,
outpatient costs, and inpatient costs. All costs were cal-
culated in Korean won (KRW) and converted into US
dollars (USD) using the yearly average exchange rate for
2013 (average rate: 1 USD = 1,113.85 KRW) and the an-
nual rate of adjustment for medical fees in the insurance
scheme to reflect inflation during 2007 and 2013 [20].
Statistical analysis
The two-sided t-test was used to make between-group
comparisons of continuous data, and the chi-square test
was used for categorical data. OS was calculated from
the date of initiation of GEM-E or GEM to the date of
last follow-up or death from any cause, using the
Kaplan-Meier method and log-rank test. Multivariate
analysis of survival was performed using the Cox
proportional-hazards model to evaluate treatment effect,
with adjustment for sex, age, and comorbidities. For the
skewed distribution of cost, treatments were compared
using the t-test after log transformation. All data manipu-
lation and statistical analyses were performed using SAS
9.1.3 (SAS institute, Cary, NC, USA). A p-value <0.05 was
considered statistically significance.
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Results
Patient characteristics
We identified 13,531 patients between January 1, 2004,
and December 31, 2012. Among them, 3,498 patients
who received chemotherapy between January 1, 2004,
and December 31, 2006, were excluded. Additionally
2,562 patients who had had surgical treatment or radio-
therapy prior to the index date were excluded. Also ex-
cluded were 1,658 patients without a history of
intervention for histological or cytological diagnosis
within one year before chemotherapy. Patients (n = 666)
who had other cancers; and patients (n = 155) with at
least one claim of pancreatic neuroendocrine cancer
(ICD-10 code: C25.4) after the index date were excluded.
Patients (n = 719) who were treated with GEM or GEM-
E concurrently with other chemotherapeutic agents were
excluded (Fig. 1).
Finally, a total of 4,267 patients who had chemo-
therapy with either GEM (n = 1,331, 31.2 %) or GEM-
E (n = 2,936, 68.8 %) satisfied the inclusion criteria. The
baseline characteristics of patients are summarized in
Table 1. The mean ages ± standard deviation (SD) of the
patients receiving GEM-E or GEM were 61.9 ± 9.8 years
and 63.4 ± 10.4 years, respectively (p < 0.0001). There were
significantly more male patients in the GEM-E group
(64.7 % vs. 59.4 %, p = 0.0010). The mean CCI scores ± SD
of the patients receiving GEM-E or GEM at the index date
were 8.88 ± 3.39 and 9.14 ± 3.40, respectively (p = 0.0206).
Clinical outcome
The survival curves for each treatment, derived from the
Kaplan-Meier estimates, are shown in Fig. 2. The me-
dian overall survival of the patients receiving GEM-E
was not significantly longer (6.77 months for GEM-E vs.
6.68 months for GEM, p = 0.0977) (Table 2). The actual
difference in median survival was 3 days (mean 20 days).
The 1-year survival rates of patients receiving GEM-E
and GEM were 27.0 and 27.3 %, respectively (p =
0.5988). Multivariate analysis using age, sex, and comor-
bidities as covariates did not reveal any significant differ-
ences in survival (hazard ratio 0.966, p = 0.3353,
Additional file 1: Table S1). For sensitivity analysis, the
follow-up period was extended for five years; however,
the median overall survival time was similar to the sur-
vival seen in the base analysis (data not shown).
Cost-effectiveness results
The total medical costs associated with treatment were
USD 3,891.53 higher per patient receiving GEM-E (USD
23,819) than the costs of those receiving GEM (USD
19,927; Table 3). The mean medication costs of the pa-
tients receiving GEM-E were significantly higher than
Fig. 1 Selection of the study population. Abbreviation: GEM, Gemcitabine; GEM-E, Gemcitabine + Erlotinib
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the costs of the patients receiving GEM group, reflecting
the cost of erlotinib (USD 3,264.00 vs. USD 1,169.20,
respectively; p < 0.0001; Table 3).
The average and incremental cost-effectiveness ratios de-
rived from the total costs and the outcome measures are
shown in Table 4. Expressed as a cost-effectiveness ratio for
an additional survival of 20 days, the incremental cost per
life year of GEM-E over GEM was estimated to be USD
70,843.64. GEM-E was not cost-effective at the Korean
willingness-to-pay (WTP) threshold of USD 27,272 [21].
Discussion
GEM has been the standard-of-care for patients with
advanced or metastatic pancreatic cancer [6], and the
addition of other chemotherapeutic agents to GEM had
failed to show superiority over GEM alone [10, 11] until
the positive result for abraxane [22]. The addition of er-
lotinib to GEM has been shown to be superior to GEM
alone with statistical significance [12, 13], but using
GEM-E instead of GEM for the modest survival differ-
ence of 2 weeks has been a matter of debate. Moreover,
there have not been additional clinical trials that have
directly compared GEM and GEM-E for advanced or
metastatic pancreatic cancer, and the data regarding
GEM-E is thus limited.
This study investigated the effectiveness of GEM-E
over GEM alone using a national population-based
claims database, and we could not find significant differ-
ences between the treatments. This is the first study, to
our knowledge, that has investigated the real-world ef-
fectiveness of GEM-E versus GEM.
Although the patients receiving GEM-E were younger
(61.9 vs 63.4 years), had lower CCI scores (8.9 vs 9.1),
and there were more males (64.7 % vs 59.4 %), compared
with the patients receiving GEM; there was no survival
advantage for the patients receiving GEM-E. Because a
higher CCI score was associated with worse survival
(Additional file 1: Table S1), it is plausible that the base-
line characteristics of the patients receiving GEM were
not favorable. However, the final outcomes, as reflected
in overall survival, were not significantly different.
There are some differences between our national, un-
selected, large study cohort in our retrospective observa-
tional study and the patients enrolled in the randomized
controlled trial (RCT) conducted by Moore et al. [12]
RCTs are an effective method for determining and valid-
ating the efficacy of a treatment, and the remarkable im-
provement in the treatment of cancer over the past few
decades can be attributed to RCTs [23, 24]. Despite the
excellent internal validity of RCTs, however, the external
Table 1 Patient baseline characteristics
GEM-E (n = 1,331) GEM (n = 2,936) p-valuea
No. (%) No. (%)
Sex
Male 861 (64.69) 1,743 (59.37) 0.0010
Female 470 (35.31) 1,193 (40.63)
Age, years
Mean ± SD 61.89 ± 9.76 63.38 ± 10.40 <0.0001
Median 63 65
Range 28–88 18–92
18–29 2 (0.15) 6 (0.20) <0.0001
30–39 16 (1.20) 42 (1.43)
40–49 128 (9.62) 268 (9.13)
50–59 387 (29.08) 683 (23.26)
60–69 486 (36.51) 1,010 (34.4)
70–79 295 (22.16) 825 (28.1)
Above 80 17 (1.28) 102 (3.47)
Charlson Comorbidity Index (CCI)




≤ 3 102 (7.66) 222 (7.56) 0.2024
4–6 246 (18.48) 476 (16.21)
7–9 302 (22.69) 664 (22.62)
10–12 511 (38.39) 1,134 (38.62)
≥ 13 170 (12.77) 440 (14.99)
Follow-up time, daysb
Mean ± SD 278.7 ± 224.7 292.3 ± 263.3
Median 210 207
Abbreviation: GEM Gemcitabine, GEM-E Gemcitabine + Erlotinib
aDifferences between GEM and GME-E were tested with t-test for continues
variable and with the chi-square test for categorical variables
bFollow-up termination: follow-up for 3 years or until December 31, 2013 or
date of death
Table 2 Summary of Effectiveness
GEM-E GEM p-valuea
(n = 1,331) (n = 2,936)
Overall survival time, months
Mean ± SD 10.48 9.86 0.0977
(325.5 days ± 8.9) (305.6 days ± 5.4)
Median 6.77 6.68
(210 days) (207 days)
Overall survival rate per treatment time, %
6 months 56.5 54.7 0.2108
12 months 27.0 27.3 0.5988
24 months 12.9 10.6 0.1350
36 months 9.3 6.5 0.0977
Abbreviation: GEM Gemcitabine, GEM-E Gemcitabine + Erlotinib
alog-rank test
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validity and generalizability of RCTs may be limited; and
data from independent patient groups are often required
to confirm RCT results. Population-based observational
research can provide data with good external validity
and can complement the limitations of RCTs. As the su-
periority of GEM-E over GEM alone was shown by only
one RCT [12], our analysis of the real-world effective-
ness of GEM-E is of value.
South Korea has universal health insurance that covers
virtually the entire population, and this study extracted
and screened all the patients with pancreatic cancer
from South Korea’s NHIS database. The study is repre-
sentative of all the patients in South Korea with ad-
vanced pancreatic cancer between 2007 and 2012, and
can provide good external validity. Moreover, comorbid-
ity data, as well as patient demographics and claims for
medical services submitted to the national insurance sys-
tem, were retrieved from the electronic database; and
these data also contribute to the strength of the external
validity.
Limitations inherent to population-based studies and
the claims-based approach affect this study. The diagno-
sis code on a claim does not necessarily verify the spe-
cific disease, since the diagnosis may be incorrectly
coded or a code may not precisely capture the diagnosis
of interest. The inclusion criterion of this study that each
patient must have received a histological or cytological
diagnosis within one year before the index date probably
reduced the sensitivity, but increased the specificity
identification of patients with pancreatic cancer. Also,
information that could have affected the study out-
comes, such as performance status is not readily
Fig. 2 Kaplan-Meier curves for overall survival. Abbreviation: GEM, Gemcitabine; GEM-E, Gemcitabine + Erlotinib
Table 3 Medical cost estimation
(Unit: USD)
GEM-E GEM p-valuea
(n = 1,331) (n = 2,936)
Inpatient cost (Mean ± SD)b 14,846.70 ± 11,865.27 13,211.07 ± 1,0931.57 <0.0001
Length of stay (Mean ± SD) 64 ± 53 63 ± 54 0.8032
Outpatient cost (Mean ± SD)b 6,152.29 ± 7,233.05 6,066.95 ± 7,001.03 0.6920
Medication cost (Mean ± SD)b 3,264.00 ± 4,579.44 1,169.20 ± 1,644.40 <0.0001
Total medical costs (Mean ± SD)b 23,819.51 ± 15,106.18 19,927.98 ± 14,444.86 <0.0001
Abbreviation: GEM Gemcitabine, GEM-E Gemcitabine + Erlotinib
aDifferences between GEM and GEM-E was tested with t-test after log transformation
bAverage 2013 exchange rate: one US dollar (USD) = 1,113.85 Korea Won (KRW)
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available from claims data. The results of our study,
thus, should be interpreted with caution; however, this is
the first and the largest study to compare effectiveness
of first chemotherapy for pancreatic cancer reflecting
the real-world clinical benefit.
Since the introduction of GEM-E as one of the
standard-of-care treatments for advanced pancreatic
cancer, other regimens also have shown superiority over
GEM alone. FOLFIRINOX (5-FU, leucovorin, irinotecan,
and oxaliplatin) first showed superiority over GEM with
better response rate (32 versus 9 %), longer progression-
free survival (6.4 versus 3.3 months), and longer survival
(11.1 versus 6.8 months) [25]. The addition of albumin-
bound (nab)-paclitaxel to GEM also resulted in better
response rate (23 versus 7 %), longer progression-free
survival (5.5 versus 3.7 months), and longer survival (8.5
versus 6.7 months) [22]. The magnitude of benefit from
these regimens, shown by the survival differences, are
absolutely larger than the benefit of GEM-E, and these
combination regimens are recommended in patients
with good performance status. Further research on the
real-world effectiveness of these newer regimens would
be needed, as these are being widely used [26]. More-
over, liposomal irinotecan (MM-398) in combination
with 5-FU and leucovorin has shown efficacy in patients
with gemcitabine refractory pancreatic cancer, and was
recently approved in the United States [27].
Because the importance of cost-effectiveness has in-
creased in relation to limited healthcare budgets and the
disproportionate rise in spending on cancer drugs, we
also performed a cost-effectiveness analysis from the
perspective of a national health insurance payer. Given
the South Korean WTP threshold of USD 27,272, GEM-
E was not cost-effective compared to GEM alone. In line
with our finding, Tam et al. examined the cost-
effectiveness of gemcitabine combinations for metastatic
pancreatic cancer and found that GEM-E was not a
cost-effective option compared with GEM alone [26].
Furthermore, they proposed FOLFIRNOX might be
cost-effective compared to GEM alone if the WTP
threshold was relatively high or if drug costs were
substantially reduced. Further studies on the cost-
effectiveness of recent chemotherapy regimens such as
FOLFIRINOX or nab-paclitaxel, in the context of a na-
tion’s WTP background, are warranted.
Conclusion
In conclusion, this national population-based study did
not prove that GEM-E was significantly superior to
GEM for pancreatic cancer, providing only a modest dif-
ference in survival. The lack of effectiveness and cost ef-
fectiveness of GEM-E in a South Korean cohort shown
in the present study suggests that reconsideration of the
use of GEM-E for pancreatic cancer is warranted and
further multinational trials are needed.
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